Navigation Links
NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test
Date:7/24/2009

FT. MYERS, Fla., July 24 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer genetics testing services announced today that it has entered into a Strategic Supply Agreement with Abbott (NYSE: ABT). The Agreement provides for Abbott to supply materials for NeoGenomics to develop its own FISH (fluorescence in situ hybridization)-based test for the diagnosis of melanoma. In a separate transaction, Abbott has also acquired 9.6% of NeoGenomics common stock for $4.8 million.

Under terms of the Strategic Supply Agreement, NeoGenomics will evaluate and select from Abbott's proprietary single FISH probes to develop and commercialize a test for melanoma diagnosis in the United States. Once the probes have been identified by NeoGenomics, Abbott will supply them (some on an exclusive basis) over the course of a ten-year term. The agreement may be expanded, under certain circumstances, to include up to two additional tests for other cancers.

According to the American Cancer Society, approximately 68,000 new cases of invasive melanoma will be diagnosed this year in the United States. Melanoma typically starts as an abnormal mole on the skin and is easily cured if caught and removed early. Once it spreads to other parts of the body, however, it is particularly deadly. NeoGenomics intends to develop a FISH test to distinguish benign versus malignant melanoma. The goal for the new test is to provide the ability to more accurately diagnose malignant melanoma and provide more accurate prognostic information, thus assisting dermatologists in better managing patient care.

"We are delighted to have entered into this strategic agreement with Abbott. Melanoma is the most serious form of skin cancer, and its incidence continues to
'/>"/>

SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
2. NeoGenomics Announces Results for the 3rd Quarter 2007
3. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
4. NeoGenomics to Present at the Noble Financial Equity Conference
5. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
6. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
7. NeoGenomics Appoints Douglas M. VanOort as Executive Chairman and Interim Chief Executive Officer
8. NeoGenomics Schedules its Q1 2009 Earnings Release for April 23, 2009
9. NeoGenomics, Inc. Reports First Quarter 2009 Financial Results
10. NeoGenomics to Present at Noble Financials 5th Annual Equity Conference on Monday, June 8th
11. NeoGenomics Schedules Its Q2 2009 Earnings Release for July 28, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Cancer Clinics of Excellence (CCE) Announces Management and Board of Directors Slate at 1st Annual General Membership Meeting 2Health News:Even before tomato warning, many Americans lacked confidence in the food safety system 2Health News:Even before tomato warning, many Americans lacked confidence in the food safety system 3Health News:Even before tomato warning, many Americans lacked confidence in the food safety system 4Health News:UCR chemists use 'green chemistry' to produce amines, chemical compounds used widely in industry 2Health News:Hoana Medical, Inc. Awarded a Federal Supply Contract Through the U.S. Department of Veteran Affairs 2Health News:National Patient Advocate Foundation Applauds Senators Lautenberg and Brown for Protecting Health Care Coverage for At-Risk Children 2Health News:National Patient Advocate Foundation Applauds Senators Lautenberg and Brown for Protecting Health Care Coverage for At-Risk Children 3Health News:The University of Arizona Program in Integrative Medicine Earns 'Center of Excellence' Designation 2Health News:The University of Arizona Program in Integrative Medicine Earns 'Center of Excellence' Designation 3
Breaking Medicine Technology:Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference 6504 1Involving family in medical rounds benefits both family and medical team 62042 1Involving family in medical rounds benefits both family and medical team 62042 2Involving family in medical rounds benefits both family and medical team 62042 3Involving family in medical rounds benefits both family and medical team 62042 4Lupus Research Institute announces 2009 novel research grants 10894 1Lupus Research Institute announces 2009 novel research grants 10894 2Lupus Research Institute announces 2009 novel research grants 10894 3